Medication-related osteonecrosis of the jaw in an older patient with multiple myeloma.

OBJECTIVE

This article reports a case of medication-related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM).

BACKGROUND

Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication-related osteonecrosis of the jaw (MRONJ).

MATERIALS AND

METHODS

A 67-year-old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ.

RESULTS

MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow-up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence.

CONCLUSION

Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.